Literature DB >> 8549766

Modulation of Tax and PKA-mediated expression of HTLV-I promoter via cAMP response element binding and modulator proteins CREB and CREM.

J Bodor1, W Walker, E Flemington, A L Spetz, J F Habener.   

Abstract

Nuclear proteins of the human peripheral blood T lymphocytes that bind to the CREs located within three 21-bp repeat enhancers of the HTLV-I promoter belong to the CREB/CREM family of bZIP transcription factors. It has been shown previously that Tax enhances transactivation of these CREs by direct interactions with the bZIP domain of the transcription factors to stabilize DNA-binding. We show that CREB and CREM bind all three CRE sequences of the HTLV-I promoter which are important determinants in Tax-elicited transactivation as well as PKA-mediated activation of the HTLV-I promoter. Tax and PKA activate transcription from a HTLV-I-LTR CAT reporter plasmid transfected to NIH 3T3 cells, and CREM attenuates the activation. In the context of a GAL4 CREB fusion protein in which the DNA-binding bZIP domain of CREB is replaced by GAL4 binding domain, a single amino acid substitution of serine-133, phosphorylated by PKA and critical for the transactivation function of CREB, attenuates both Tax and PKA-mediated transcriptional responses. These observations suggest that Tax enhances CREB-mediated transactivation of the HTLV-I promoter by a mechanism apart from, and/or in addition to, the reported stabilization of DNA-binding by interaction with the bZIP domain of CREB.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8549766     DOI: 10.1016/0014-5793(95)01299-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Luman, a new member of the CREB/ATF family, binds to herpes simplex virus VP16-associated host cellular factor.

Authors:  R Lu; P Yang; P O'Hare; V Misra
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Immortalization of T lymphocytes by human T-cell leukemia virus type 1 is independent of the tax-CBP/p300 interaction.

Authors:  M D Robek; L Ratner
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Molecular interactions involved in the transactivation of the human T-cell leukemia virus type 1 promoter mediated by Tax and CREB-2 (ATF-4).

Authors:  F Gachon; S Thebault; A Peleraux; C Devaux; J M Mesnard
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

4.  Human T-cell leukemia virus type 2 tax mutants that selectively abrogate NFkappaB or CREB/ATF activation fail to transform primary human T cells.

Authors:  T M Ross; M Narayan; Z Y Fang; A C Minella; P L Green
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 5.  CRE-decoy oligonucleotide-inhibition of gene expression and tumor growth.

Authors:  Y S Cho-Chung; Y G Park; M Nesterova; Y N Lee; Y S Cho
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

Review 6.  Mechanisms of T-cell activation by human T-cell lymphotropic virus type I.

Authors:  P Höllsberg
Journal:  Microbiol Mol Biol Rev       Date:  1999-06       Impact factor: 11.056

7.  Differential requirements for activation of integrated and transiently transfected human T-cell leukemia virus type 1 long terminal repeat.

Authors:  Masahiko Okada; Kuan-Teh Jeang
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

8.  Immortalization of CD4(+) and CD8(+) T lymphocytes by human T-cell leukemia virus type 1 Tax mutants expressed in a functional molecular clone.

Authors:  M D Robek; L Ratner
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 9.  Epigenetics, drugs of abuse, and the retroviral promoter.

Authors:  Jasmine Shirazi; Sonia Shah; Divya Sagar; Michael R Nonnemacher; Brian Wigdahl; Zafar K Khan; Pooja Jain
Journal:  J Neuroimmune Pharmacol       Date:  2013-11-12       Impact factor: 4.147

10.  Cotranscriptional Chromatin Remodeling by Small RNA Species: An HTLV-1 Perspective.

Authors:  Nishat Aliya; Saifur Rahman; Zafar K Khan; Pooja Jain
Journal:  Leuk Res Treatment       Date:  2012-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.